Valneva to cut up to 15% of jobs as reduced travel hits vaccine demand on May 14, 2026 Dukoral geopolitical factors guidance cut Ixchiq Ixiaro layoffs Lyme Disease operating costs restructuring travel Vaccines Valneva VLA15 workforce reduction +
Pfizer and Valneva's Lyme Vaccine Misses Primary Endpoint But Pursue Regulatory Approval on March 23, 2026 Clinical Research Lyme Disease Pfizer regulatory approval Vaccine Efficacy Vaccines Valneva VALOR +
FDA Suspends Valneva's Chikungunya Vaccine, Ixchiq, Due to Serious Safety Concerns on August 25, 2025 Adverse event Cessation of life chikungunya vaccine Encephalitis Hospitalization Ixchiq license suspension Safety United States Food and Drug Administration Valneva +
EU Lifts Restriction on Valneva's Chikungunya Vaccine for Older Adults, Recommends Caution on July 14, 2025 Adverse event chikungunya vaccine concerns Elderly (population group) European Medicines Agency Ixchiq label extension Safety Valneva +